• Publications
  • Influence
The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s
The National Institute on Aging and the Alzheimer’s Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer’s disease (AD), referred toExpand
  • 3,879
  • 432
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25Expand
  • 1,120
  • 105
  • Open Access
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease
In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer'sExpand
  • 1,360
  • 104
  • Open Access
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
BACKGROUND The order and magnitude of pathologic processes in Alzheimer's disease are not well understood, partly because the disease develops over many years. Autosomal dominant Alzheimer's diseaseExpand
  • 2,030
  • 66
  • Open Access
The Role of Apolipoprotein E in Alzheimer's Disease
The epsilon4 allele of apolipoprotein E (APOE) is the major genetic risk factor for Alzheimer's disease (AD). Although there have been numerous studies attempting to elucidate the underlyingExpand
  • 1,091
  • 56
  • Open Access
Alzheimer’s Disease: The Challenge of the Second Century
In the first of our State of the Art Review series, David M. Holtzman, John C. Morris, and Alison M. Goate explore the rapid pace of Alzheimer’s disease research and the challenges to translatingExpand
  • 879
  • 53
  • Open Access
National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards
Background and Purpose— One in 3 individuals will experience a stroke, dementia or both. Moreover, twice as many individuals will have cognitive impairment short of dementia as either stroke orExpand
  • 1,176
  • 50
  • Open Access
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Human apolipoprotein E has three isoforms: APOE2, APOE3 and APOE4. APOE4 is a major genetic risk factor for Alzheimer’s disease and is associated with Down’s syndrome dementia and poor neurologicalExpand
  • 677
  • 48
apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.
Neurotoxic amyloid beta peptide (Abeta) accumulates in the brains of individuals with Alzheimer disease (AD). The APOE4 allele is a major risk factor for sporadic AD and has been associated withExpand
  • 529
  • 46
  • Open Access
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.
Microglia play a pivotal role in the maintenance of brain homeostasis but lose homeostatic function during neurodegenerative disorders. We identified a specific apolipoprotein E (APOE)-dependentExpand
  • 554
  • 44